My sister-in-law works for AZ, selling Farxiga (competitor to Jardiance), she thinks the combination market is challenging and diffucult to develop. But the apabetalone additive comibination results with that class of drug from BoM is VERY substantial and intriguing, and can't be ignored.

Also, think I have read that Farxiga has been gaining ground on Jardiance, and with the BoM data and discoveries, thinking apabetalone could be a very nice competitive portfolio builder with either company (Jardiance vs Farxiga)?

Makes sense that apabetalone has not been tested as a standalone first therapy for the types of very sick patients in previous studies. But once approved, at some point it might make sense to study the initial standalone effects and benefits as primary or secondary sub-group future studies, with apporpriate patient selection?